MML Investors Services
IMDX

MML Investors Services’s Insight Molecular Diagnostics IMDX Stock Holding History

MML Investors Services’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,275
Closed -$38K – 2108
2022
Q1 		$38K Hold
1,275
– – ﹤0.01% 2044
2021
Q4 		$55K Buy
+1,275
New +$73.3K ﹤0.01% 1995

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

MML Investors Services's IMDX Position: Q2 2022 in Review

MML Investors Services sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 1,275 shares — an estimated $38K sold.

MML Investors Services first reported a position in IMDX in Q4 2021 and held it in 2 quarters. The position peaked at $55K in Q4 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • MML Investors Services reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • MML Investors Services sold 1,275 Insight Molecular Diagnostics shares in Q2 2022, an estimated $38K.
  • MML Investors Services first reported a position in Insight Molecular Diagnostics in Q4 2021 and held it in 2 quarters.
  • MML Investors Services's Insight Molecular Diagnostics position peaked at $55K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on MML Investors Services's 13F filing for Q2 2022, filed 12 Aug 2022.